CJC-1295 with DAC and CJC-1295 without DAC are two different peptides that share a name. Both are 29-residue GHRH(1-29) analogues with the same four amino acid substitutions. The DAC version has an extra C-terminal lysine carrying a maleimidopropionyl group that binds albumin, which changes its mass, CAS number and reported half-life.
At a glance
| Name | Other names | Length | Formula | MW (g/mol) | CAS | Key structural feature |
|---|---|---|---|---|---|---|
| CJC-1295 without DAC | Modified GRF (1-29), Mod GRF 1-29, tetrasubstituted GRF(1-29) | 29 residues | C152H252N44O42 | ~3367.9 | None consistently listed | GHRH(1-29) amide with D-Ala2, Gln8, Ala15, Leu27 |
| CJC-1295 with DAC | CJC-1295 DAC, DAC:GRF | 30 residues | C165H269N47O46 | ~3647.3 | 446262-90-4 | Same four substitutions plus Lys30 bearing a maleimidopropionyl (MPA) group for covalent albumin binding |
| Ipamorelin | NNC 26-0161 | 5 residues | C38H49N9O5 | ~711.9 | 170851-70-4 | Aib-His-D-2Nal-D-Phe-Lys-NH2; ghrelin receptor (GHS-R1a) agonist |
Background: GHRH(1-29) and sermorelin
Native growth hormone-releasing hormone (GHRH) is a 44-residue hypothalamic peptide. Its first 29 residues, GHRH(1-29)-NH2 (sermorelin), retain receptor activity. In plasma the native fragment is cleaved quickly, mainly at the Ala2–Asp3 bond, so it lasts only minutes. CJC-1295 was developed by ConjuChem to address this; its authors stated that use of GHRH was limited by its short duration of action [3].
CJC-1295 without DAC (Modified GRF 1-29)
Modified GRF (1-29) is GHRH(1-29)-NH2 with four substitutions:
- Position 2: L-Ala → D-Ala (resists DPP-IV cleavage)
- Position 8: Asn → Gln (avoids deamidation)
- Position 15: Gly → Ala
- Position 27: Met → Leu (removes an oxidation-prone methionine)
Sequence: Tyr-D-Ala-Asp-Ala-Ile-Phe-Thr-Gln-Ser-Tyr-Arg-Lys-Val-Leu-Ala-Gln-Leu-Ser-Ala-Arg-Lys-Leu-Leu-Gln-Asp-Ile-Leu-Ser-Arg-NH2 (one-letter: YaDAIFTQSYRKVLAQLSARKLLQDILSR-NH2, where “a” is D-Ala). The formula is C152H252N44O42 and the average MW is about 3367.9. These values follow from the sermorelin formula (C149H246N44O42S) plus the four substitutions. No CAS number is consistently listed for this peptide in authoritative databases, so vendor CAS numbers should be checked against the structure.
CJC-1295 with DAC
CJC-1295 with DAC uses the same tetrasubstituted 1-29 chain and adds a lysine at position 30. That lysine’s ε-amine carries a 3-maleimidopropionyl group, which ConjuChem called the Drug Affinity Complex (DAC). The maleimide is designed to react with the free thiol of Cys34 on serum albumin, forming a covalent peptide–albumin conjugate. In preclinical work, Jetté et al. reported that hGRF(1-29)–albumin bioconjugates activated the GRF receptor in rat anterior pituitary and identified CJC-1295 as a long-lasting analogue [1]. Alba et al. reported on CJC-1295 in GHRH knockout mice [2]. The formula is C165H269N47O46, the MW is about 3647.3, and the CAS number is 446262-90-4.
Why “CJC-1295” alone is ambiguous
In the ConjuChem publications, “CJC-1295” means the DAC-bearing compound [1][3][4]. In the research-peptide market, “CJC-1295” is often used for Mod GRF 1-29, which has no DAC. The two compounds differ by about 279 Da, have different CAS listings, and are not interchangeable. Some literature and vendor listings mix up the names or pair one compound’s CAS number with the other’s structure. When you read a paper or a label, check the sequence, formula and observed mass, not just the name.
Published human studies of CJC-1295 (with DAC)
Teichman et al. (2006) reported two randomized, placebo-controlled, double-blind, ascending-dose trials of the DAC compound in healthy adults [3]. The authors reported prolonged increases in plasma GH and IGF-I after a single administration and an estimated half-life of 5.8–8.1 days. Ionescu and Frohman (2006) studied GH secretion patterns in healthy men and reported that pulsatile GH secretion persisted while trough GH levels and IGF-I rose [4]. These studies measured pharmacokinetic and endocrine endpoints only. No CJC-1295 product, with or without DAC, has been approved by the FDA.
Ipamorelin
Ipamorelin is a pentapeptide, Aib-His-D-2Nal-D-Phe-Lys-NH2, where Aib is α-aminoisobutyric acid and D-2Nal is D-3-(2-naphthyl)alanine. The formula is C38H49N9O5, the MW is about 711.9, and the CAS number is 170851-70-4. It acts on the ghrelin receptor (GHS-R1a), not the GHRH receptor, so it works through a different receptor pathway from either CJC-1295 compound. Raun et al. (1998, Novo Nordisk) described ipamorelin as the first selective GH secretagogue; in their in vitro and animal models it released GH without the ACTH or cortisol increases seen with some earlier GHRPs [5]. Gobburu et al. (1999) reported pharmacokinetic–pharmacodynamic modelling of ipamorelin in human volunteers [6].
Helsinn later studied ipamorelin in a postoperative setting (NCT00672074) [7]. In the published Phase II proof-of-concept trial, Beck et al. (2014) reported no significant differences from placebo on the key or secondary efficacy analyses [8]. Ipamorelin is not FDA-approved.
Analytical notes
- Mass spectrometry tells them apart. The average masses are about 3367.9 (no DAC), 3647.3 (DAC) and 711.9 (ipamorelin). The large peptides show multiply charged ions in ESI-MS (for example [M+3H]3+, [M+4H]4+), so check the deconvoluted mass against the expected value. MS-based identification of CJC-1295 in an unlabelled preparation has been reported in the doping-control literature [9].
- HPLC purity is a separate measure. RP-HPLC (UV, typically 214–220 nm) reports the share of the main peak. It does not by itself confirm identity, so it should be paired with MS.
- DAC reactivity. The maleimide in the DAC compound reacts with thiols and can hydrolyze. Ring-opened or adduct species may show up as related-substance peaks with shifted masses.
- Blends need each component measured. In a CJC-1295 (no DAC) + ipamorelin blend, one overall purity number does not show the amount or identity of each peptide. A useful certificate reports each component separately: identity by MS, purity, and ideally the amount per vial.
Regulatory status
- FDA: Neither CJC-1295 compound nor ipamorelin is an FDA-approved drug. FDA’s page on bulk drug substances that may present significant safety risks in compounding (content current as of April 2026) describes concerns for both, including possible immunogenicity and impurity and characterization complexity, and lists reported adverse events [10].
- WADA: The 2026 Prohibited List, under S2, names “GHRH and its analogues” with CJC-1293, CJC-1295, sermorelin and tesamorelin as examples, and growth hormone secretagogues and their mimetics with ipamorelin among the examples. These are prohibited at all times [11].
Kalibra research materials
Kalibra supplies these compounds as separate, clearly labelled research materials: CJC-1295 (no DAC), CJC-1295 with DAC, Ipamorelin, and a CJC-1295 (no DAC) + Ipamorelin blend. To check identity and purity data for any lot, see How to read a peptide Certificate of Analysis.
Frequently asked questions
Is CJC-1295 without DAC the same as Modified GRF (1-29)?
Yes. “CJC-1295 without DAC” and “Modified GRF (1-29)” both refer to GHRH(1-29)-NH2 with D-Ala2, Gln8, Ala15 and Leu27 substitutions (C152H252N44O42, about 3367.9 g/mol). It has no lysine–maleimidopropionyl extension.
How can a lab confirm which CJC-1295 it has?
Use mass spectrometry. The deconvoluted average mass is about 3367.9 for the version without DAC and about 3647.3 for the DAC version. Pair this with HPLC purity, and check that the stated sequence and CAS number match the observed mass.
What half-life was reported for CJC-1295 with DAC?
Teichman et al. (2006) reported an estimated half-life of 5.8–8.1 days for the DAC compound, attributed to albumin binding. Those trials did not study the version without DAC.
Are CJC-1295 or ipamorelin approved for human use?
No. Neither CJC-1295 compound nor ipamorelin is FDA-approved. FDA has described safety concerns for both in the compounding context, and WADA’s 2026 Prohibited List names CJC-1295 and ipamorelin under S2. Kalibra products are for laboratory research use only.
References
- Jetté L, Léger R, Thibaudeau K, et al. Human growth hormone-releasing factor (hGRF)1-29-albumin bioconjugates activate the GRF receptor on the anterior pituitary in rats: identification of CJC-1295 as a long-lasting GRF analog. Endocrinology. 2005;146(7):3052-3058. PubMed 15817669
- Alba M, Fintini D, Sagazio A, et al. Once-daily administration of CJC-1295, a long-acting growth hormone-releasing hormone (GHRH) analog, normalizes growth in the GHRH knockout mouse. Am J Physiol Endocrinol Metab. 2006;291(6):E1290-E1294. PubMed 16822960
- Teichman SL, Neale A, Lawrence B, Gagnon C, Castaigne JP, Frohman LA. Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults. J Clin Endocrinol Metab. 2006;91(3):799-805. PubMed 16352683
- Ionescu M, Frohman LA. Pulsatile secretion of growth hormone (GH) persists during continuous stimulation by CJC-1295, a long-acting GH-releasing hormone analog. J Clin Endocrinol Metab. 2006;91(12):4792-4797. PubMed 17018654
- Raun K, Hansen BS, Johansen NL, et al. Ipamorelin, the first selective growth hormone secretagogue. Eur J Endocrinol. 1998;139(5):552-561. PubMed 9849822
- Gobburu JV, Agersø H, Jusko WJ, Ynddal L. Pharmacokinetic-pharmacodynamic modeling of ipamorelin, a growth hormone releasing peptide, in human volunteers. Pharm Res. 1999;16(9):1412-1416. PubMed 10496658
- ClinicalTrials.gov. NCT00672074 (ipamorelin, Helsinn). clinicaltrials.gov/study/NCT00672074
- Beck DE, Sweeney WB, McCarter MD, et al. Prospective, randomized, controlled, proof-of-concept study of the ghrelin mimetic ipamorelin for the management of postoperative ileus in bowel resection patients. Int J Colorectal Dis. 2014;29(12):1527-1534. PubMed 25331030
- Henninge J, Pepaj M, Hullstein I, Hemmersbach P. Identification of CJC-1295, a growth-hormone-releasing peptide, in an unknown pharmaceutical preparation. Drug Test Anal. 2010;2(11-12):647-650. PubMed 21204297
- U.S. Food and Drug Administration. Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety Risks. Content current as of April 2026. fda.gov
- World Anti-Doping Agency. The 2026 Prohibited List, section S2. wada-ama.org/en/prohibited-list
For Research Use Only. Not for human or veterinary use. Not for use in diagnostic or therapeutic procedures. This guide summarizes published literature for laboratory reference and is not medical advice.
